High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.

Blood
A BadrosGuido Tricot

Abstract

Standard allogeneic stem cell transplant (allo-SCT) regimens have been associated with a high transplant-related mortality (TRM) in multiple myeloma (MM). Nonmyeloablative therapy can establish stable engraftment after allo-SCT and maintain the antitumor effect with less toxicity, which is important in heavily pretreated and elderly patients. We report on 16 poor-risk MM patients receiving allo-SCT from an HLA-matched (n = 14) or mismatched (n = 2) sibling following conditioning with melphalan 100 mg/m(2) (MEL-100). Ten patients had refractory relapse, 4 responsive relapse, and 2 patients were in near complete remission (nCR) with poor-prognosis disease. Patients had received 1 (n = 9) or 2 (n = 7) prior autotransplants. Donor lymphocyte infusions (DLIs) were given to 14 patients with no clinical evidence of graft versus host disease (GVHD) either to attain full donor chimerism (n = 4) or to eradicate residual disease (n = 10). Fifteen patients showed myeloid engraftment, and 12 patients were full donor chimeras at day +21. No TRM was observed during the first 100 days. Acute GVHD developed in 10 patients; 1 had fatal grade IV GVHD. Seven progressed to chronic GVHD, limited in 3 and extensive in 4 patients. At a median follow-u...Continue Reading

References

Jun 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G GahrtonP Jacobs
Feb 1, 1997·Hematology/oncology Clinics of North America·W I BensingerG Gahrton
Nov 5, 1999·Current Opinion in Hematology·C Craddock
Nov 5, 1999·Current Opinion in Hematology·F Dazzi, J Goldman
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LokhorstL F Verdonck

❮ Previous
Next ❯

Citations

Nov 8, 2003·International Journal of Hematology·Naoki TakezakoAtsushi Togawa
Nov 15, 2002·International Journal of Hematology·Bart Barlogie, John D Shaughnessy
Apr 30, 2003·Current Treatment Options in Oncology·Seema Singhal, Jayesh Mehta
Apr 30, 2004·Current Treatment Options in Oncology·Paul RichardsonKenneth C Anderson
Apr 1, 2008·Current Hematologic Malignancy Reports·Shaji Kumar
Mar 20, 2004·Lancet·Bhawna Sirohi, Ray Powles
Jun 29, 2007·Nature Clinical Practice. Oncology·Ben SprangersAn D Billiau
Dec 12, 2001·British Journal of Haematology·UNKNOWN UK myeloma forum. British Committee for Standards in Haematology
Aug 30, 2002·British Journal of Haematology·Athanasios B-T FassasGuido Tricot
Jan 25, 2003·British Journal of Haematology·Juan José LahuertaUNKNOWN Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea
Mar 6, 2003·Reviews in Clinical and Experimental Hematology·Roberto Bellucci, Jerome Ritz
Apr 26, 2002·Cancer Practice·Helen Kim
Aug 31, 2002·Journal of Hematotherapy & Stem Cell Research·Michael A MorseH Kim Lyerly
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·F Baron, Y Beguin
Mar 7, 2002·Current Opinion in Oncology·Carol Ann Huff, Richard J Jones
May 2, 2002·Anti-cancer Drugs·S Zweegman, P C Huijgens
Mar 7, 2002·Current Opinion in Pediatrics·K Scott Baker, John E Wagner
Oct 18, 2001·Current Opinion in Hematology·K S Peggs, S Mackinnon
Oct 18, 2001·Current Opinion in Hematology·L RuggeriA Velardi
Oct 18, 2003·Current Opinion in Hematology·Joseph H Antin
May 26, 2005·International Journal of Hematology·Chihiro ShimazakiUNKNOWN Japan Myeloma Study Group
Oct 7, 2005·International Journal of Hematology·Naoya OchiaiChihiro Shimazaki
Aug 9, 2003·Drugs·Leonard T Heffner, Sagar Lonial
May 4, 2013·Immunotherapy·Najla El-JurdiMohamed A Kharfan-Dabaja
Sep 29, 2005·Hematology·Bo Björkstrand
Nov 1, 2005·Bone Marrow Transplantation·P HariD H Vesole
Jun 14, 2003·Leukemia & Lymphoma·Athanasios B T FassasGuido Tricot
Jan 14, 2012·Leukemia & Lymphoma·Jean El-CheikhDidier Blaise
Jun 7, 2006·Leukemia & Lymphoma·Evangelos TerposMeletios-Athanassios Dimopoulos
Oct 31, 2006·Leukemia & Lymphoma·Susann SzmaniaFrits van Rhee
Apr 25, 2007·Leukemia & Lymphoma·Ignazio MajolinoUNKNOWN Gitmo Institutions
Jan 26, 2006·Expert Opinion on Investigational Drugs·Teru HideshimaKenneth C Anderson
Feb 26, 2014·Seminars in Oncology·Donald M EicherHeesun J Rogers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.